NCT01624025View on ClinicalTrials.gov

A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

February 29, 2016

Conditions
Metastatic Advanced Gastric Cancer
Interventions
OTHER

Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.

Trial Locations (1)

120-752

Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01624025 - A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin | Biotech Hunter | Biotech Hunter